Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2025-01-06 00:00:00 ET · period of report 2025-01-02 · accession 0001453687-25-000024 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-06 | 2025-01-02 | RNAC | ZENNER PATRICK J | Dir | A - Grant | $0.00 | +2,600 | 10.4K | +33% | $0 |
| D | 2025-01-06 | 2025-01-02 | RNAC | ZENNER PATRICK J | Dir | A - Grant | $0.00 | +7,800 | 7,800 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-02 | A | A | 2,600 | $0.00 | 10,374 | D | — | — | (F1) Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026. (F2) On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-01-02 | A | A | 7,800 | $0.00 | 7,800 | D | $16.93 · 2026-01-02 to 2035-01-01 | 7,800 Common Stock |